Table 1

Echocardiographic measurements in transgenic mice and non transgenic littermates with or without treatment of PKCβ inhibitor (LY333531)

Nontreated Treated with PKCβ inhibitor
Control (n = 6)Transgenic (n = 6)Control (n = 6)Transgenic (n = 6)
LVEDD, mm3.41 ± 0.292.91 ± 0.36*3.30 ± 0.263.36 ± 0.26
LVESD, mm1.76 ± 0.241.93 ± 0.341.77 ± 0.162.01 ± 0.17
FS, %48.4 ± 2.633.8 ± 7.5*46.3 ± 4.340.0 ± 2.3**
IVS, mm0.42 ± 0.030.61 ± 0.03*0.42 ± 0.030.39 ± 0.03
PW, mm0.39 ± 0.020.64 ± 0.05*0.38 ± 0.050.38 ± 0.04
LV mass, mg30.4 ± 4.340.5 ± 9.9*28.8 ± 6.327.8 ± 5.3
Body weight, g26.2 ± 3.325.4 ± 3.123.0 ± 2.223.7 ± 2.5
LV mass/body weight1.17 ± 0.151.61 ± 0.38*1.25 ± 0.261.18 ± 0.23
Heart rate, b.p.m.405 ± 54363 ± 34434 ± 44372 ± 49
  • LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; IVS, interventricular septal wall thickness; PW left ventricular posterior wall thickness; FS, left ventricular fractional shortening = (LVEDD-LVESD)/LVEDD × 100. 

  • *P < 0.05 vs. nontreated control. 

  • **P < 0.05 vs. treated control (ANOVA with Student–Newman–Keuls test).